Basking Biosciences is pioneering a novel approach to treating acute thrombosis, particularly focusing on acute ischemic stroke. Their lead drug candidate, BB-031, is a first-in-class reversible RNA aptamer that targets von Willebrand Factor, aiming to provide a safer and more effective thrombolytic therapy. This innovative therapy is designed to be rapidly neutralized in case of bleeding complications, addressing a significant unmet need in the field. The ongoing Phase II RAISE trial is currently evaluating BB-031's efficacy and safety in patients, with additional research being conducted for its application in treating pulmonary embolism and other thrombotic conditions.

The foundation of Basking's technology lies in two decades of research on RNA aptamers, conducted by the company's founders, Bruce Sullenger, Ph.D., and Shahid Nimjee, M.D., Ph.D. These aptamers exhibit high target affinity and specificity, with a short half-life, allowing for precision-based therapeutic targeting. The mechanism of action for BB-031 is centered on its ability to selectively inhibit von Willebrand Factor, which plays a crucial role in blood clotting. This targeted approach not only enhances the therapeutic potential of the treatment but also expands access to acute revascularization therapies for a broader patient population.

United States

Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2023 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.

Basking Biosciences

Company Details